VARIANTYX  POSTS

ACMG secondary findings updated list for reporting of secondary findings, for medically actionable genes in clinical exome and genome sequencing

ACMG secondary findings updated list for reporting of secondary findings, for medically actionable genes in clinical exome and genome sequencing.    The American College of …

Read More

Medically actionable genes that go beyond the ACMG set of 59

In this post we’ll explore examples of these other genes that are not part of the ACMG’s recommended set, but are similar in that they have some associated actionability and could likewise impact medical management and decision making …

Read More

Unavoidable vs optional incidental findings: What you need to know

Given that genome sequencing has the potential to identify tens of thousands of variants in every patient sample tested, our GCs are often asked about how we handle incidental findings in our reporting. In this post we’ll explore the different types of possible findings and describe our reporting policies …

Read More

FXN: What you need to know for Friedreich’s ataxia patients

It’s well known that FXN repeat expansions cause Friedreich’s ataxia, but in certain cases, the affected individual is compound heterozygous for an expansion plus another pathogenic variant.

Read More

Is WGS-based testing relevant for patients with suspected mitochondrial disease?

In short, yes! But let’s take a step back and start with what mitochondrial disease is.

Read More

Variantyx Inc.

1671 Worcester Road, Suite 300
Framingham MA 01701 USA

Phone: +1 617-209-2090

  • This site is protected by reCAPTCHA and the Google Privacy and Terms of Service apply

Please do not submit Protected Health Information (PHI) through this email address.

If you need to submit Protected Health Information (PHI), please call us at 617-209-2090 and we will work with you to submit the information through an alternate mechanism.

Otherwise, please continue: